LEXX (Lexaria Bioscience) Company Cash Volume

Official company branding of Lexaria (LEXX)

Lexaria Bioscience revenues rely on licensing agreements for the implementation of its absorption platform. The DehydraTECH technologies, which optimize substance bioavailability, provide high industry authority. The operating model is based on Canadian laboratories and US bio-factories, eliminating downtime. The free cash flow metric demonstrates liquidity, where the 0.00 level indicates the parameter's status, confirming the business's financial autonomy.

LEXX - Lexaria Bioscience Corp. Company Cash Volume over the range 07/04/2022 - 11/21/2026

Analytical breakdowns for Lexaria Bioscience (LEXX)

- stock value and consensus price forecast:
Basic company analysis:LEXX Lexaria Bioscience Corp.
Brand item of Lexaria

For Lexaria Bioscience (LEXX), financial stability depends directly on the ability to cover R&D and DehydraTECH validation costs prior to securing major licensing deals. By analyzing current cash reserves, an investor assesses liquidity relative to market capitalization, which allows for the determination of the business's margin of safety and the adjustment of the asset's fair value to account for capital shortage risks.

Competitors of Lexaria Bioscience (LEXX)

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ORMP: Company Cash on Hand|ENTX (Entera Bio Ltd) - Company Cash and Cash Equivalents|HYFT: Company Cash Volume|Company Cash on Hand ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Company Cash Volume|Company Cash Funds QNTM|Company Cash Volume FGEN|Company Cash on Hand Telomir Pharmaceuticals TELO|Company Cash Volume RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Company Total Cash Volume|RLYB - Company Cash Funds|Company Cash Balance PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Company Cash Funds|Company Cash on Hand Aptorum|Company Cash on Hand LYRA|Impact BioMedical Inc - Company Total Cash Volume|Company Cash Volume TNFA|YCBD - Company Cash Reserve|PainReform Ltd. - Company Cash on Hand|CYTO (Auris Medical) - Company Total Cash Volume|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance